CR20190464A - Combinación farmacéutica que comprende ponesimod - Google Patents
Combinación farmacéutica que comprende ponesimodInfo
- Publication number
- CR20190464A CR20190464A CR20190464A CR20190464A CR20190464A CR 20190464 A CR20190464 A CR 20190464A CR 20190464 A CR20190464 A CR 20190464A CR 20190464 A CR20190464 A CR 20190464A CR 20190464 A CR20190464 A CR 20190464A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ponesimod
- que
- pharmaceutical combination
- active ingredient
- ingrediente
- Prior art date
Links
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 title abstract 3
- 229950009275 ponesimod Drugs 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960000681 leflunomide Drugs 0.000 abstract 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 abstract 2
- 229960000331 teriflunomide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055994 | 2017-03-14 | ||
| PCT/EP2018/056185 WO2018167030A1 (en) | 2017-03-14 | 2018-03-13 | Pharmaceutical combination comprising ponesimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190464A true CR20190464A (es) | 2019-11-26 |
Family
ID=61655772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190464A CR20190464A (es) | 2017-03-14 | 2018-03-13 | Combinación farmacéutica que comprende ponesimod |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11723896B2 (https=) |
| EP (1) | EP3595657A1 (https=) |
| JP (3) | JP7281406B2 (https=) |
| KR (1) | KR102574562B1 (https=) |
| CN (1) | CN110381942B (https=) |
| AU (2) | AU2018233109B2 (https=) |
| BR (1) | BR112019018894A2 (https=) |
| CA (1) | CA3056301C (https=) |
| CL (1) | CL2019002525A1 (https=) |
| CO (1) | CO2019008510A2 (https=) |
| CR (1) | CR20190464A (https=) |
| DO (1) | DOP2019000257A (https=) |
| EA (1) | EA201992117A1 (https=) |
| EC (1) | ECSP19073317A (https=) |
| IL (1) | IL269239B2 (https=) |
| JO (1) | JOP20190207A1 (https=) |
| MA (1) | MA49822A (https=) |
| MX (1) | MX390941B (https=) |
| NI (1) | NI201900092A (https=) |
| PE (1) | PE20191489A1 (https=) |
| PH (1) | PH12019502110A1 (https=) |
| SG (1) | SG11201907308UA (https=) |
| UA (1) | UA125756C2 (https=) |
| WO (1) | WO2018167030A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| CA2400290A1 (en) * | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
| EP1381356B1 (en) | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| PT1689726E (pt) | 2003-11-21 | 2010-12-09 | Actelion Pharmaceuticals Ltd | Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores |
| CA2584655A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| US8263780B2 (en) | 2006-11-23 | 2012-09-11 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US20120172427A1 (en) | 2009-09-18 | 2012-07-05 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
| EP2598126A2 (en) | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
| WO2012018704A1 (en) | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| WO2016079687A1 (en) | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| EP4056179A1 (en) | 2014-12-11 | 2022-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| CA2987798A1 (en) | 2015-06-18 | 2016-12-22 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/en not_active Ceased
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/en active Pending
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 CA CA3056301A patent/CA3056301C/en active Active
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US12527772B2/en active Active
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
-
2025
- 2025-12-22 US US19/429,084 patent/US20260108501A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000257A (es) | Combinación farmacéutica que comprende ponesimod | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| CY1124041T1 (el) | Συνθεσεις που περιλαμβανουν κυκλοσπορινη | |
| MX383931B (es) | Compuestos de aza-piridona y usos de estos. | |
| MX2019014445A (es) | Preparacion hidratante topica. | |
| IN2014CH00840A (https=) | ||
| GEP20237486B (en) | Formulations of copanlisib | |
| UY36273A (es) | Composicion para el tratamiento de neuropatías y del dolor neuropático | |
| CL2018000282A1 (es) | Amida seleccionada de ácido gamma-hidroxibutírico y usos de la misma en el tratamiento de abuso de alcohol | |
| MX373197B (es) | Formulaciones estables de undecanoato de testosterona. | |
| CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
| GB2554966B (en) | Deodorizing combination of active ingredients | |
| BR112019001024A2 (pt) | combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas | |
| SV2017005417A (es) | Composición farmacéutica solida que comprende amlodipino y losartán | |
| BR112018017214A2 (pt) | preparação contendo esomeprazol | |
| BR112018001793A2 (pt) | preparação cosmética de redução do suor | |
| BR112017022340A2 (pt) | 2-tiopirimidinonas | |
| CO2019005180A2 (es) | Composición que contiene alulosa para promover la excreción de lípidos vegetales del cuerpo | |
| MX385115B (es) | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta. | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
| EA201791483A1 (ru) | Фармацевтическая композиция для лечения микоза | |
| MX2020004731A (es) | Terapias de combinacion de inhibidor ezh2. | |
| MX2018003381A (es) | Profilactico o agente terapeutico para queratitis fungica. | |
| MA39009A (fr) | Compositions pharmaceutiques comprenant un agent actif | |
| CL2016003273A1 (es) | Composiciones antimicrobianas con agentes efervescentes |